Percheron Therapeutics Ltd
ASX:PER
Percheron Therapeutics Ltd
Research & Development
Percheron Therapeutics Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Percheron Therapeutics Ltd
ASX:PER
|
Research & Development
-AU$10.8m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-20%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Research & Development
-AU$17.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Research & Development
-AU$30m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-9%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Research & Development
-AU$66.9m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Research & Development
-AU$4.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
Percheron Therapeutics Ltd
Glance View
Percheron Therapeutics Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The firm is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
See Also
What is Percheron Therapeutics Ltd's Research & Development?
Research & Development
-10.8m
AUD
Based on the financial report for Jun 30, 2025, Percheron Therapeutics Ltd's Research & Development amounts to -10.8m AUD.
What is Percheron Therapeutics Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-20%
Over the last year, the Research & Development growth was -1%. The average annual Research & Development growth rates for Percheron Therapeutics Ltd have been -33% over the past three years , -41% over the past five years , and -20% over the past ten years .
